GeoVax Labs, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 28 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 10 Jul 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 31 Mar 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →GeoVax Labs, Inc. — Overview & Financial Snapshot
GeoVax Labs, Inc. (NasdaqCM: GOVX) is a Healthcare company, ranked #3,021 of 6,774 companies globally and #1,162 of 4,000 in United States on PositoAI, with a Positivity Score of 20,937. Its market capitalisation is ₹20.28 Cr ($2.15M), P/E ratio is -0.0 and P/B ratio is 1.22. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 4/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →